CLINICAL NEWS
The AAP and the CDC have have amended and expanded their recommendations for the use of Tdap, according to a policy statement published online September 26 in Pediatrics. » More
|
|
There is a strong relationship between bivalirudin dosing requirements and renal function when steady state conditions are maintained, results of a study published in the September issue of Pharmacotherapy demonstrate. » More |
|
Asthma may contribute to poor glycemic control in youth with diabetes, especially if the disease is left untreated, according to the results of a study published online September 26 in Pediatrics. » More |
Survey
a) We follow the CMS-approved compendia. If a medication is listed, it is approved. We do not follow any pathway.
b) We follow the CMS-approved compendia, but a medication is only approved when it follows a pathway.
c) We follow internal guidelines. No pathway is required.
d) We follow internal guidelines, with only specific pathways.
Respond Here and see what your colleagues are using too.
Want to see the results of our last survey regarding Medco's acquisition by Express Scripts?
Click Here. |
Editor's Pick
COPD
Management of chronic obstructive pulmonary disease: An emphasis on recently approved medications and products in the pipeline. » Click here. |
|
Novartis has filed for marketing authorization with the European Medicines Agency of its investigational drug, NVA237 (glycopyrronium bromide), the drug company announced at the European Respiratory Society in Amsterdam, The Netherlands. » More |
|
Saw palmetto fruit extract has no effect on lower urinary tract (UT) symptoms attributed to BPH, regardless of dose, a study published in The Journal of the American Medical Association found. » More |
|
In patients with relapsing forms of MS, once-daily oral teriflunomide 14 mg significantly reduced the annual relapse rate and disability progressions, and improved several MRI measures of disease activity, according to a study recently published in The New England Journal of Medicine. » More |
FDA ACTIONS
FDA has approved ipratropium bromide and albuterol (Combivent Respimat Inhalation Spray, Boehringer Ingelheim) for patients with COPD using a regular aerosol bronchodilator and who require a second bronchodilator. » More |
|
FDA has approved sitagliptin and simvastatin (Juvisync, MSD International GmbH Clonmel), a fixed-dose combination prescription medication, for use by adults who have type 2 diabetes and high cholesterol levels. » More |
|
FDA recently approved tadalafil (Cialis, Eli Lilly) tablets for once-daily use for the treatment of 3 indications: ED, the signs and symptoms of BPH, and ED and the signs and symptoms of BPH in men who have both conditions. » More |
|
Confirm your
e-newsletter subscription click here.
To ensure future delivery of email newsletters from Formulary please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff |
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|
